

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
20 October 2022 (20.10.2022)



(10) International Publication Number
WO 2022/221695 A1

(51) International Patent Classification:

A61K 9/127 (2006.01) C12N 15/90 (2006.01)
A61K 9/51 (2006.01)

MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

(21) International Application Number:

PCT/US2022/025074

Declarations under Rule 4.17:

— of inventorship (Rule 4.17(iv))

(22) International Filing Date:

15 April 2022 (15.04.2022)

Published:

— with international search report (Art. 21(3))
— before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/176,228 17 April 2021 (17.04.2021) US
63/274,171 01 November 2021 (01.11.2021) US
63/316,575 04 March 2022 (04.03.2022) US

(71) Applicant: INTELLIA THERAPEUTICS, INC.

[US/US]; 40 Erie Street, Cambridge, MA 02139 (US).

(72) Inventors: SWAMI, Archana; c/o Intellia Therapeu-

tics, Inc., 40 Erie Street, Cambridge, MA 02139 (US).
RAKSHE, Vishal; c/o Intellia Therapeutics, Inc., 40 Erie
Street, Cambridge, MA 02139 (US). PRODEUS, Aaron;
c/o Intellia Therapeutics, Inc., 40 Erie Street, Cambridge,
MA 02139 (US). MAETANI, Micah; c/o Intellia Thera-
peutics, Inc., 40 Erie Street, Cambridge, MA 02139 (US).
PARMAR, Rubina, Giare; c/o Intellia Therapeutics, Inc.,
40 Erie Street, Cambridge, MA 02139 (US).

(74) Agent: HALSTEAD, David, P. et al.; Foley Hoag LLP,

155 Seaport Boulevard, Boston, MA 02210-2600 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH,
KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA,
MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM,
ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,

(54) Title: LIPID NANOPARTICLE COMPOSITIONS

(57) Abstract: The disclosure provides lipid nanoparticle (LNP) compositions of ionizable lipids, helper lipids, neutral lipids, and PEG lipids useful for the delivery of biologically active agents, for example delivering biologically active agents to cells to prepare engineered cells. The LNP compositions disclosed herein are useful in methods of gene editing and methods of delivering a biologically active agent and methods of modifying or cleaving DNA.



WO 2022/221695 A1